『2 Minutes with Joey - ABBV Stock News』のカバーアート

2 Minutes with Joey - ABBV Stock News

2 Minutes with Joey - ABBV Stock News

著者： 2 Minutes with Joey
無料で聴く

Two minutes with Joey on AbbVie (ABBV) - a quick daily recap of what the stock did today and why, in plain English. Information and entertainment only, not financial advice.Copyright 2 Minutes with Joey 社会科学
エピソード
  • ABBV Today - Aug 13: Solid Day on the Street

    ABBV Today - Aug 13: Solid Day on the Street
    2026/08/13
    Hey there! It's Joey, your friendly investor buddy, breaking down what went down with AbbVie today. So, ABBV had a solid day, up about 1.6%. Not too shabby!

    Now, let’s talk about what happened. The stock was pretty active, trading around 1 million shares today, which is right on par with its usual hustle. It opened strong and kept the momentum going, hitting a high of about 255. That kind of action gets people interested, you know?

    So, why the good vibes? Well, there’s been some chatter around AbbVie’s pipeline and its recent quarterly results. They dropped some strong numbers for Q2 and even raised guidance for 2026, which definitely turned some heads. Investors love to see that kind of optimism! Plus, Wolfe Research gave a nod to AbbVie, saying it’s looking good in the grand scheme of things compared to its peers. With new approvals coming down the line, folks are feeling pretty bullish about their future.

    Also, there’s been some buzz comparing AbbVie to companies like Johnson & Johnson and Pfizer. Some analysts are saying AbbVie’s dividend yield is looking pretty appealing, especially when you stack it up against the competition. It’s always nice to know you’re holding onto something that might pay off down the road.

    One thing to keep an eye on is how these approvals and pipeline developments play out. If they keep landing those approvals, it could really shift the narrative around AbbVie, making it even more attractive for investors.

    So, to wrap it up, AbbVie had a nice little bump today, and the news around its earnings and future outlook is definitely giving it some steam. Just remember, this info is for fun and to keep you in the loop, not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • ABBV Today - Aug 12: Downgrade Hits AbbVie

    ABBV Today - Aug 12: Downgrade Hits AbbVie
    2026/08/12
    Hey there! It’s Joey, your friendly stock enthusiast. I’ve been investing for years, and today, I’m breaking down AbbVie, or ABBV, and it was a red day—down just a smidge, like 0.1%. Not a huge drop, but still a bummer.

    So, here’s the scoop. AbbVie kind of coasted today, barely moving at all. It’s like when you’re just chilling on the couch, not really doing much. The stock was hovering around $249.83, so not a wild ride. But what’s interesting is that BTIG decided to downgrade Apogee Therapeutics, which is tied to AbbVie’s recent deal. That probably made some folks a bit uneasy, you know?

    Now, onto the why. The market’s always got its ears perked up, and when news like a downgrade drops, people start hitting the sell button fast. It’s a chain reaction—when one piece of news hits, it can shake things up for other related stocks. Plus, there’s been chatter comparing AbbVie with CVS Health and Pfizer lately. Everyone’s trying to figure out who’s the better buy, and that’s always gonna cause some waves. It’s like a high school popularity contest, but for stocks.

    Oh, and here’s a little tidbit for you—AbbVie is waiting on the FDA to review a new use for BOTOX. That could be a game-changer if it goes through, so keep an eye on that.

    Alright, that’s a wrap for today! Just remember, this is all for fun and info, not financial advice. Stay curious, and I’ll catch you later!
    続きを読む 一部表示
    1 分
  • ABBV Today - Aug 11: $8 Billion Debt Deal

    ABBV Today - Aug 11: $8 Billion Debt Deal
    2026/08/11
    Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today, we’re talking about AbbVie. So, how did it do? Well, it was a pretty chill day, barely moved, closing up just a smidge at 0.26%.

    So, what’s the scoop? AbbVie just took on a whopping $8 billion in debt for its Apogee deal. Yeah, that one stung a bit for some folks. When you hear “debt,” it usually raises eyebrows, especially for dividend investors. People were wondering if this move might hurt their precious payouts down the line.

    Now, here’s the thing. Some analysts are a bit worried about AbbVie’s earnings potential. Like, Erste Group Bank just lowered its EPS estimates for FY2027. That’s not exactly a warm hug for investors looking for growth. And to add to the mix, BNP Paribas adjusted their price target on AbbVie to $247, which is a bit of a bump up from where it was, but they’re still neutral on the stock. So, it’s like, they’re saying, “We see potential, but we’re not super excited about it.”

    But don’t let that totally bring you down. AbbVie did post some strong Q2 earnings recently, which had some investors feeling a little more optimistic. It’s like they’re trying to balance the good with the not-so-good.

    One thing worth knowing about is that this big debt deal might signal AbbVie’s plans to invest heavily in its pipeline. They’re all about growth, and sometimes you gotta take risks to get there. So, keep an eye on how they manage this debt and what it means for their future projects.

    Alright, that’s the lowdown on AbbVie today! Remember, this is just for fun and info—no financial advice here. Catch you later!
    続きを読む 一部表示
    2 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません